Business plan

GNI: Business Plan and Growth Potential

© 2022 GNI Group Ltd. All rights reserved

Securities Code: 21610

Warning

Forward-looking statements

  • Statements contained herein regarding our current plans, estimates and strategies that are not historical facts are forward-looking statements.

  • Forward-looking statements are based on the beliefs of our management in light of currently available information. Actual results may differ materially from these forward-looking statements due to a variety of risks and uncertainties. Accordingly, please do not rely on these forward-looking statements in making investment decisions.

  • Important factors that could affect actual results include economic and/or regulatory conditions affecting the Group’s business segments, market trends and global conditions.

  • Note: In some places, pro forma figures may be rounded to emphasize the direction of the business.

Key Updates

Summary

Mainland of Beijing (BC)

F351 The Phase III clinical trial started in January 2022 for HBV-induced liver fibrosis targeting the application of NMPA in the second quarter of 2024 in China.

F573 The phase I clinical trial also started in January 2022 for acute/acute over chronic liver failure also in China.

Cullgen Inc.

Conduct the PROTAC drug molecule pre-IND consultation with Chinas NMPA.

  • business Finance

    • – Consolidated revenue reached 12,690 million yen in fiscal 2021, the highest in history

    • – BC has applied to list H shares on the main board of the Hong Kong Stock Exchange (HKEx).

  • 1. Company Profile

  • 2. Business

  • 3. Growth strategy

  • 4. Companies

  • 5. Market environment

  • 6. Business Outlook

  • 7. Risk Considerations

Registered Address

company profile

Nihonbashi-Honcho YS Bldg. 3F 2-2-2 Nihonbashi-Honcho, Chuo-ku,

Tokyo 103-0023, Japan

Business

A global healthcare company focused on the development and distribution of pharmaceutical drugs and biomaterials

Establishment

November 2001

President and CEO

Ying Luo, Ph.D.

Paid-up capital 10,884 million yen

(at the end of December 2021)

Employees (aggregate)

629 full-time employees

(at the end of December 2021)

SEO

Tokyo Stock Exchange Mother Market

(August 2007 / Code: 2160)

Listener

Grant Thornton Taiyo LLC

This is an excerpt from the original content. To continue reading it, access the original document here.

Warning

GNI Group Limited published this content on March 31, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 31, 2022 07:05:09 UTC.


Source link